Abstract

Inflammatory bowel disease (IBD), clinically defined as Crohn’s disease (CD), ulcerative colitis (UC), or IBD-unclassified, results in chronic inflammation of the gastrointestinal tract in genetically susceptible hosts. Pediatric onset IBD represents ≥ 25% of all IBD diagnoses and often presents with intestinal stricturing, perianal disease, and failed response to conventional treatments. NOD2 was the first and is the most replicated locus associated with adult IBD, to date. However, its role in pediatric onset IBD is not well understood. We performed whole-exome sequencing on a cohort of 1,183 patients with pediatric onset IBD (ages 0–18.5 years). We identified 92 probands with biallelic rare and low frequency NOD2 variants accounting for approximately 8% of our cohort, suggesting a Mendelian inheritance pattern of disease. Additionally, we investigated the contribution of recessive inheritance of NOD2 alleles in adult IBD patients from a large clinical population cohort. We found that recessive inheritance of NOD2 variants explains ~ 7% of cases in this adult IBD cohort, including ~ 10% of CD cases, confirming the observations from our pediatric IBD cohort. Exploration of EHR data showed that several of these adult IBD patients obtained their initial IBD diagnosis before 18 years of age, consistent with early onset disease. While it has been previously reported that carriers of more than one NOD2 risk alleles have increased susceptibility to Crohn’s Disease (CD), our data formally demonstrate that recessive inheritance of NOD2 alleles is a mechanistic driver of early onset IBD, specifically CD, likely due to loss of NOD2 protein function. Collectively, our findings show that recessive inheritance of rare and low frequency deleterious NOD2 variants account for 7–10% of CD cases and implicate NOD2 as a Mendelian disease gene for early onset Crohn’s Disease.

Highlights

  • Inflammatory bowel disease (IBD), clinically defined as Crohn’s disease (CD), ulcerative colitis (UC), or IBD-unclassified, results in chronic inflammation of the gastrointestinal tract in genetically susceptible hosts

  • Variation in nucleotide-binding and oligomerization domain-containing 2 (NOD2) accounts for approximately 20% of the genetic risk among Crohn’s Disease (CD) cases, with three variants—p.R702W (ExAC MAF = 0.0227 across all populations), p.G908R (ExAC MAF = 0.0099), and p.L1007fs (ExAC MAF = 0.0131)—accounting for over 80% of the disease-causing mutations in NOD2 associated with adult ­CD33, albeit not with UC; and ileal versus colonic ­CD34

  • We use the term inflammatory bowel disease (IBD) throughout to encompass diagnoses of both Ulcerative Colitis and Crohn’s disease in the DiscovEHR cohort, which is similar to the referral diagnosis of the pediatric patients where some had diagnoses of ulcerative colitis, Crohn’s disease, or IBD unspecified (Table S1)

Read more

Summary

Introduction

Inflammatory bowel disease (IBD), clinically defined as Crohn’s disease (CD), ulcerative colitis (UC), or IBD-unclassified, results in chronic inflammation of the gastrointestinal tract in genetically susceptible hosts. Variation in NOD2 accounts for approximately 20% of the genetic risk among CD cases, with three variants—p.R702W (ExAC MAF = 0.0227 across all populations), p.G908R (ExAC MAF = 0.0099), and p.L1007fs (ExAC MAF = 0.0131)—accounting for over 80% of the disease-causing mutations in NOD2 associated with adult ­CD33, albeit not with UC; and ileal versus colonic ­CD34 These three “common” risk variants, typically observed in a heterozygous state, are predicted to be loss-of-function alleles that impair NF-κB activation in response to MDP ligands, in vitro[28,35,36,37]. As the mechanism for these “common” IBD susceptibility loci in the pathogenesis of early onset IBD remains u­ nclear[44], we performed whole-exome sequencing and rare variant analysis on a cohort of 1,183 pediatric onset IBD patients to elucidate the role of rare protein coding variation in IBD-associated genes, NOD2, in this disease

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call